Tivozanib

Fotivda (tivozanib) is a small molecule pharmaceutical. Tivozanib was first approved as Fotivda on 2017-08-24. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, and vascular endothelial growth factor receptor 1. Fotivda's patents are valid until 2023-11-16 (FDA).